Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results

      - Reports Full-Year Diluted EPS of $5.28 on a GAAP Basis, an Increase of 44.3 Percent; Adjusted Diluted EPS of $8.94, an Increase of 13.0 Percent

      - Full-Year Net Revenues Were $33.266 Billion, an Increase of 1.6 Percent on a GAAP Basis; Adjusted Net Revenues Grew 2.7 Percent Operationally; Excluding the Unfavorable Impact of International HUMIRA Net Revenues Due to Biosimilar Competition, Full-Year Adjusted Net Revenues Grew 9.9 Percent Operationally

      - Full-Year U.S. HUMIRA Net Revenues Were $14.864 Billion, an Increase of 8.6 Percent; Internationally, HUMIRA Net Revenues Were $4.305 Billion, a Decrease of 31.1 Percent on a Reported Basis, or 27.8 Percent Operationally, Due to Biosimilar Competition

      - Full-Year Global Net Revenues From the Hematologic Oncology Portfolio Were $5.466 Billion, an Increase of 39.0 Percent on a Reported Basis, or 39.3 Percent Operationally; Full-Year Global IMBRUVICA Net Revenues Were $4.674 Billion, an Increase of 30.2 Percent, with U.S. Net Revenues of $3.830 Billion and International Profit Sharing of $844 Million; Global VENCLEXTA Net Revenues Were $792 Million

      - Full-Year Global SKYRIZI Net Revenues Were $355 Million; Global RINVOQ Net Revenues Were $47 Million; AbbVie Expects SKYRIZI and RINVOQ Combined Revenues of Approximately $1.700 Billion in 2020

      - Reports Fourth-Quarter Diluted EPS of $1.88 on a GAAP Basis; Adjusted Diluted EPS of $2.21

      - Fourth-Quarter Net Revenues Were $8.704 Billion, an Increase of 4.8 Percent on a GAAP Basis, or 5.3 Percent Operationally; Excluding the Unfavorable Impact of International HUMIRA Net Revenues Due to Biosimilar Competition, Fourth-Quarter Net Revenues Grew 11.0 Percent Operationally

      - AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep; AbbVie Expects to Close the Pending Allergan Transaction in the First Quarter 2020

      - Provides Standalone 2020 GAAP Diluted EPS Guidance Range of $7.66 to $7.76, Representing Growth of 46.0 Percent at the Midpoint; Provides Standalone 2020 Adjusted Diluted EPS Guidance Range of $9.61 to $9.71, Representing Growth of 8.1 Percent at the Midpoint; Expects Standalone 2020 Revenue Growth Approaching 8.0 Percent on an Operational Basis


      News provided by

      AbbVie

      Feb 07, 2020, 07:43 ET

      Share this article

      Share this article


      NORTH CHICAGO, Ill., Feb. 7, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2019.

      "Our strong performance this quarter completes another excellent year for AbbVie," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "The launches of Skyrizi and Rinvoq are going extremely well, and we are entering 2020 with substantial momentum. We also look forward to completing the planned Allergan acquisition in the first quarter."

      Fourth-Quarter Results

      • Worldwide net revenues were $8.704 billion, an increase of 4.8 percent on a reported basis, or 5.3 percent operationally. Excluding the unfavorable impact of international HUMIRA net revenues due to biosimilar competition, fourth-quarter net revenues grew 11.0 percent operationally.
      • U.S. HUMIRA net revenues were $3.969 billion, an increase of 9.8 percent. Internationally, HUMIRA net revenues were $948 million, a decrease of 27.3 percent on a reported basis, or 25.4 percent operationally, due to biosimilar competition. Global HUMIRA net revenues of $4.917 billion were flat on a reported basis and increased 0.5 percent operationally.
      • Global IMBRUVICA net revenues were $1.296 billion, an increase of 28.9 percent, with U.S. net revenues of $1.073 billion and international profit sharing of $223 million. Global VENCLEXTA net revenues were $251 million. Global net revenues from the hematologic oncology portfolio were $1.547 billion, an increase of 37.0 percent on a reported basis, or 37.2 percent operationally.
      • Global SKYRIZI net revenues were $216 million and global RINVOQ net revenues were $33 million.
      • On a GAAP basis, the gross margin ratio in the fourth quarter was 77.0 percent. The adjusted gross margin ratio was 81.6 percent.
      • On a GAAP basis, selling, general and administrative expense was 22.4 percent of net revenues. The adjusted SG&A expense was 21.6 percent of net revenues.
      • On a GAAP basis, research and development expense was 17.7 percent of net revenues. The adjusted R&D expense was 15.3 percent of net revenues, reflecting funding actions supporting all stages of our pipeline.
      • On a GAAP basis, the operating margin in the fourth quarter was 45.5 percent. The adjusted operating margin was 44.6 percent.
      • On a GAAP basis, net interest expense was $455 million. The adjusted net interest expense was $282 million.
      • On a GAAP basis, the tax rate in the quarter was 8.9 percent. The adjusted tax rate was 8.8 percent.
      • Diluted EPS in the fourth quarter was $1.88 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $2.21.

      Note: "Operational" comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates.

      Recent Events

      • AbbVie and Allergan announced that Allergan has entered into definitive agreements to divest brazikumab and Zenpep in conjunction with the ongoing regulatory approval process for AbbVie's acquisition of Allergan. AstraZeneca will acquire brazikumab, an investigational IL-23 inhibitor in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights. Nestle will acquire and take full operational ownership of Zenpep, a treatment for exocrine pancreatic insufficiency, as well as Viokace, another pancreatic enzyme preparation, as part of the transaction. The closings of the divestitures of brazikumab and Zenpep are contingent upon receipt of U.S. Federal Trade Commission and European Commission (EC) approval, closing of AbbVie's pending acquisition of Allergan and the satisfaction of other customary closing conditions. AbbVie and Allergan continue to expect to close the pending transaction in the first quarter of 2020.
      • AbbVie announced regulatory approvals for RINVOQ (upadacitinib) for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA). The approvals from the EC and the Japanese Ministry of Health, Labour and Welfare are based on results from the SELECT Phase 3 program, one of the largest registrational Phase 3 programs in RA, with approximately 4,400 patients evaluated across five studies.
      • AbbVie announced positive top-line data from the Phase 3 SELECT-PsA 1 study, the second of two registration-enabling trials evaluating RINVOQ in psoriatic arthritis (PsA). In this study, both doses of RINVOQ (15 mg and 30 mg, once daily) met the primary endpoint of ACR20 at week 12 versus placebo in adult patients with active PsA who have responded inadequately or are intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs). RINVOQ also demonstrated significant improvements in signs and symptoms of the disease across a variety of endpoints compared to placebo. Both doses of RINVOQ also significantly inhibited radiographic progression at week 24 compared to placebo. The 30 mg dose of RINVOQ achieved superiority to adalimumab in terms of ACR20 response at week 12, whereas both doses achieved non-inferiority vs. adalimumab. The safety profile of RINVOQ was consistent with previously reported results across indications, with no new safety risks detected. Detailed data from both pivotal studies will be presented at an upcoming medical meeting and AbbVie expects to submit our regulatory applications for RINVOQ in PsA in the second quarter of this year.
      • AbbVie announced positive data from a head-to-head Phase 3 study evaluating SKYRIZI (risankizumab) compared to Cosentyx in adult patients with moderate to severe plaque psoriasis. In the study, SKYRIZI met both primary endpoints and all ranked secondary endpoints, demonstrating higher rates of skin clearance compared to Cosentyx. SKYRIZI met the primary endpoint of superiority with at least a 90 percent improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52. Of patients treated with SKYRIZI, 87 percent achieved PASI 90 compared to 57 percent of Cosentyx-treated patients at 52 weeks. At week 16, SKYRIZI met the other primary endpoint of non-inferiority to Cosentyx, with 74 percent of SKYRIZI patients achieving PASI 90 compared to 66 percent of Cosentyx patients. SKYRIZI also showed superiority compared to Cosentyx for all ranked secondary endpoints, including PASI 100, and PASI 75, as well as a static Physician Global Assessment score of clear or almost clear at week 52. The safety profile of SKYRIZI was consistent with that observed in previously reported studies, with no new safety signals observed through week 52. SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
      • At the American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, AbbVie presented data for RINVOQ, HUMIRA (adalimumab) and SKYRIZI, with 38 abstracts presented across multiple rheumatic conditions, including RA, ankylosing spondylitis (AS) and PsA. Included in the presentations were new data from the Phase 2/3 SELECT-AXIS 1 trial in which twice as many adult patients with active AS treated with RINVOQ achieved the primary endpoint of Assessment of SpondyloArthritis International Society (ASAS) 40 response at week 14 versus placebo. The safety profile of RINVOQ was consistent with that of previous studies in rheumatoid arthritis, with no new safety risks detected. AbbVie also presented long-term data from the SELECT Phase 3 program further evaluating efficacy and safety across measures with RINVOQ, even without methotrexate, in patients with moderate to severe RA.
      • AbbVie announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for VENCLYXTO (venetoclax) in combination with obinutuzumab for the treatment of patients with chronic lymphocytic leukemia (CLL) who were previously untreated. The CHMP positive opinion is based on results from the Phase 3 CLL14 clinical trial, which showed that patients who completed one year of treatment with VENCLYXTO plus obinutuzumab had prolonged progression-free survival (PFS) and higher rates of minimal residual disease (MRD) negativity compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil. This represents the third positive CHMP opinion for VENCLYXTO and if approved by the EC, VENCLYXTO plus obinutuzumab would be the first chemotherapy-free, oral combination regimen given with a fixed duration for patients with previously-untreated CLL. Venetoclax is being developed by AbbVie and Roche and is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.
      • AbbVie announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IMBRUVICA (ibrutinib) in combination with rituximab for the first-line treatment of younger patients (70 years old or younger) with CLL or small lymphocytic lymphoma (SLL). The application is being reviewed under the FDA's Real-Time Oncology Review pilot program and is based on results from the Phase 3 E1912 study, which showed significantly improved PFS and overall survival (OS) in patients treated with IMBRUVICA plus rituximab compared to those treated with fludarabine, cyclophosphamide and rituximab (FCR). Safety data were consistent with the known safety profile of IMBRUVICA and if approved, the milestone will mark the 11th FDA approval for IMBRUVICA across six distinct disease areas. IMBRUVICA is jointly developed and commercialized with Janssen Biotech, Inc.
      • At the American Society of Hematology Annual Meeting & Exposition (ASH), AbbVie presented data from more than 40 abstracts, including 18 oral presentations, featuring the latest scientific progress from its Hematologic Oncology programs. Key data presentations included new data from the Phase 2 CAPTIVATE study evaluating IMBRUVICA plus VENCLEXTA (venetoclax) in previously untreated patients with CLL; new data from the Phase 3 E1912 study evaluating IMBRUVICA plus rituximab versus FCR in front-line CLL, results of a 7.5-year pooled analysis for IMBRUVICA monotherapy showing earlier treatment extended PFS and increased the likelihood of a complete response in patients with relapsed/refractory mantle cell lymphoma; updated data from the Phase 3 MURANO trial four-year analysis demonstrating PFS and OS benefits with VENCLEXTA plus rituximab in patients with relapsed/refractory CLL; and results from a Phase 2 study of navitoclax in combination with ruxolitinib showing clinically meaningful spleen responses, reductions in allelic burden and improvements in total symptom score, as well as improvements in bone marrow fibrosis.
      • AbbVie announced that the CHMP of the EMA has recommended a change to the marketing authorization for MAVIRET (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. If approved by the EC, MAVIRET will be the only pan-genotypic 8-week treatment option for treatment-naïve, chronic HCV patients, without cirrhosis or with compensated cirrhosis. The positive recommendation is supported by data from the Phase 3b EXPEDITION-8 study, which showed that with 8 weeks of MAVIRET, an overall 98 percent patients achieved a sustained virologic response 12 weeks after treatment (SVR12), and for patients with GT3, the SVR12 rate was over 95%. A final EC decision is expected in 2020.
      • AbbVie and Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers targeting both solid tumors and hematologic malignancies, announced an exclusive worldwide option and license transaction for HPN217, Harpoon's B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC), and an expansion of their existing discovery collaboration for up to six additional targets. These agreements build upon the discovery collaboration established by the two companies in October 2017 and are expected to advance and broaden the use of Harpoon's proprietary TriTAC platform. The collaboration broadens AbbVie's oncology research platform to expand the development of potentially life-changing treatments for patients.
      • AbbVie announced a collaboration with Scripps Research to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis. Under the terms of the license agreement, Scripps Research will continue to conduct pre-clinical research and development activities and, in some cases, Phase 1 clinical trials with AbbVie having an exclusive option to further develop and commercialize. The collaboration broadens AbbVie's research platform to expand the development of potentially life-changing treatments for patients.
      • The Chinese health authorities have requested supply of Aluvia (lopinavir/ritonavir) as part of the government's broader efforts to address the coronavirus crisis in China. In response to this request, AbbVie has confirmed a donation of Aluvia as an experimental option to support this growing public health crisis.

      Full-Year 2020 Outlook

      AbbVie is issuing its standalone GAAP diluted EPS guidance for the full-year 2020 of $7.66 to $7.76, representing growth of 46.0 percent at the midpoint. AbbVie expects to deliver standalone adjusted diluted EPS for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. The company's standalone 2020 adjusted diluted EPS guidance excludes $1.95 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items. 

      AbbVie expects standalone revenue growth approaching 8.0 percent on an operational basis.

      Statements Required by the Irish Takeover Rules

      The directors of AbbVie accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of AbbVie (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

      Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

      About AbbVie

      AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.  In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

      Conference Call

      AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our fourth-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central time.

      Non-GAAP Financial Results

      Financial results for 2019 and 2018 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. The company's 2020 financial guidance is also being provided on both a reported and a non-GAAP basis.

      Forward-Looking Statements

      Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the possibility that the proposed acquisition of Allergan will not be pursued, failure to obtain necessary regulatory approvals or required financing or to satisfy any of the other conditions to the proposed acquisition, failure to realize the expected benefits of the proposed acquisition, failure to promptly and effectively integrate Allergan's businesses, significant transaction costs and/or unknown or inestimable liabilities, potential litigation associated with the proposed acquisition, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2018 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission (SEC). AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

      Profit Forecasts

      AbbVie is issuing its GAAP diluted EPS guidance for the full-year 2020 of $7.66 to $7.76, representing growth of 46.0 percent at the midpoint.

      AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint.

      AbbVie expects adjusted diluted EPS guidance for the first quarter of 2020 of between $2.28 and $2.30, excluding approximately 53 cents of non-cash amortization and other specified items.

      The guidance statements above regarding GAAP EPS and adjusted EPS for the full-year 2020 and adjusted EPS for the first quarter of 2020 each constitute a profit forecast for the purposes of the Rule 28 of the Irish Takeover Rules.

      The company will issue 2020 proforma guidance following the close of the planned Allergan acquisition.

      * Adjusted Earnings Per Share ("EPS") is a non-GAAP diluted earnings per share, typically reported in AbbVie's quarterly and annual financial results for the full year guidance and in the earnings calls for the next quarter guidance updates. This is not prepared in accordance with U.S. GAAP. This non-GAAP financial measure should not be considered in isolation from, as a substitute for, or superior to financial measures prepared in accordance with U.S. GAAP.

      Adjusted EPS is calculated as net income excluding certain non-cash items and factors which are unusual or unpredictable, which include: amortization and impairment of intangible assets; change in fair value of contingent consideration; major restructuring costs, integration and other related transaction costs relating to acquisitions; litigation reserves; R&D milestones and acquired IPR&D, together with the tax effects of all these items.

      Basis of Preparation

      The AbbVie profit forecasts (the "Profit Forecasts") are based on the forecast of the results for the twelve months ending December 31, 2020.

      In accordance with Rule 28 of the Irish Takeover Rules, the directors of AbbVie confirm that the Profit Forecasts have been properly compiled on the basis of the assumptions stated below on a basis consistent with the accounting policies of AbbVie, which are in accordance with U.S. GAAP and those which AbbVie anticipates will be applicable for the full year ending December 31, 2020 (as adjusted for AbbVie non-GAAP policy to disclose adjusted earnings excluding specified items).

      The AbbVie non-GAAP profit forecast does not include the proposed acquisition of Allergan. However, the AbbVie GAAP profit forecast includes estimated one-time expenses relating to the transaction such as financing costs, legal, consultants, accountants, regulatory and other fees, which are expected to be incurred in the first quarter of 2020.

      Principal Assumptions

      The Profit Forecasts have been compiled on the basis of the following assumptions:

      Assumptions which are within AbbVie's influence or control:

      • Executed licensing and partnership collaboration transaction impacts and transactions expected to be executed in the next quarter are included. In line with AbbVie's historical practices, management continues to evaluate and pursue opportunities for further partnership collaborations and in-licensing transactions. No material acquisitions or disposals are anticipated in 2020;
      • There will be no material change in the operational strategy or current management of AbbVie during the year ending December 31, 2020 other than those already announced;
      • There will be no major site closures or rationalization during the twelve-month forecast period to December 31, 2020 other than those already commenced; and
      • Share repurchases and issuances are expected to be relatively flat during the twelve-month forecast period to December 31, 2020.

      Assumptions which are outside of AbbVie's influence or control:

      • There will be no material supply chain, manufacturing and distribution disruptions and other business interruptions, including natural disasters or industrial disputes;
      • There will be no material adverse events that affect AbbVie's key products, including adverse regulatory and clinical findings or publications, product recalls, liability claims, or loss of patent protection;
      • There will be no material changes to current litigation provisions due to a new or ongoing litigation claim;
      • There will be no material change in general market, economic, competitive environments or levels of demand in countries in which AbbVie operates that would materially affect AbbVie's business;
      • There will be no material change to AbbVie customers' agreements, rebates, or discount programs from those currently prevailing;
      • There will be no changes in exchange rates, interest rates, bases of taxes, tax laws or interpretations, or legislative or regulatory requirements from those currently prevailing that would have a material impact on AbbVie's operations or its accounting policies;
      • There will be no material change to discount rate assumptions for calculating the fair value of contingent consideration from those currently prevailing; and
      • There will be no intangible asset impairments due to unfavorable clinical study results or safety signals.

      AbbVie Inc.

      Key Product Revenues

      Quarter Ended December 31, 2019

      (Unaudited)









      % Change vs. 4Q18


      Net Revenues (in millions)




      International

      Total


      U.S.


      Int'l.


      Total


      U.S.


      Operational


      Reported

      Operational


      Reported

      ADJUSTED NET REVENUESa

      $6,429


      $2,275


      $8,704


      13.0%


      (11.5)%


      (13.1)%

      5.3%


      4.8%

      Immunology

      4,195


      971


      5,166


      16.0


      (23.6)


      (25.5)

      5.5


      5.0

      Humira

      3,969


      948


      4,917


      9.8


      (25.4)


      (27.3)

      0.5


      —

      Skyrizi

      193


      23


      216


      n/m


      n/m


      n/m

      n/m


      n/m

      Rinvoq

      33


      —


      33


      n/m


      n/m


      n/m

      n/m


      n/m
















      Hematologic Oncology

      1,230


      317


      1,547


      32.6


      58.6


      57.4

      37.2


      37.0

      Imbruvicab

      1,073


      223


      1,296


      28.0


      33.8


      33.8

      28.9


      28.9

      Venclexta

      157


      94


      251


      75.8


      >100.0


      >100.0

      >100.0


      >100.0
















      HCV

      306


      326


      632


      (25.1)


      (27.6)


      (28.1)

      (26.4)


      (26.7)

      Mavyret

      306


      322


      628


      (25.4)


      (20.8)


      (21.4)

      (23.1)


      (23.4)

      Viekira

      —


      4


      4


      n/m


      (91.1)


      (90.5)

      (89.7)


      (89.1)
















      Other Key Products

      780


      506


      1,286


      (3.0)


      (3.7)


      (5.1)

      (3.2)


      (3.8)

      Creon

      292


      —


      292


      11.5


      n/a


      n/a

      11.5


      11.5

      Lupron

      174


      45


      219


      (11.3)


      16.5


      13.7

      (6.6)


      (7.1)

      Synthroid

      204


      —


      204


      (2.2)


      n/a


      n/a

      (2.2)


      (2.2)

      Synagis

      —


      261


      261


      n/a


      (1.2)


      (1.4)

      (1.2)


      (1.4)

      Duodopa

      25


      93


      118


      8.3


      6.9


      3.1

      7.1


      4.1

      Sevoflurane

      21


      60


      81


      13.9


      (8.6)


      (10.4)

      (3.6)


      (5.0)

      Kaletra

      8


      46


      54


      (41.8)


      (34.0)


      (35.6)

      (35.3)


      (36.6)

      AndroGel

      23


      —


      23


      (69.1)


      n/a


      n/a

      (69.1)


      (69.1)

      Orilissa

      33


      1


      34


      >100.0


      n/m


      n/m

      >100.0


      >100.0


      Note: "Operational" comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates.


      n/a = not applicable

      n/m = not meaningful


      a   Adjusted net revenues exclude specified items. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Percentage change is calculated using adjusted net revenues.


      b  Reflects profit sharing for Imbruvica international revenues.

      AbbVie Inc.

      Key Product Revenues

      Twelve Months Ended December 31, 2019

      (Unaudited)









      % Change vs. 12M18


      Net Revenues (in millions)




      International

      Total


      U.S.


      Int'l.


      Total


      U.S.


      Operational


      Reported

      Operational


      Reported

      ADJUSTED NET REVENUESa

      $23,907


      $9,359


      $33,266


      11.1%


      (13.4)%


      (16.5)%

      2.7%


      1.6%

      Immunology

      15,222


      4,349


      19,571


      11.2


      (27.1)


      (30.4)

      (0.8)


      (1.8)

      Humira

      14,864


      4,305


      19,169


      8.6


      (27.8)


      (31.1)

      (2.9)


      (3.9)

      Skyrizi

      311


      44


      355


      n/m


      n/m


      n/m

      n/m


      n/m

      Rinvoq

      47


      —


      47


      n/m


      n/m


      n/m

      n/m


      n/m
















      Hematologic Oncology

      4,351


      1,115


      5,466


      35.4


      56.7


      55.1

      39.3


      39.0

      Imbruvicab

      3,830


      844


      4,674


      29.1


      35.8


      35.8

      30.2


      30.2

      Venclexta

      521


      271


      792


      >100.0


      >100.0


      >100.0

      >100.0


      >100.0
















      HCV

      1,473


      1,456


      2,929


      (9.0)


      (24.7)


      (27.1)

      (17.7)


      (19.0)

      Mavyret

      1,473


      1,420


      2,893


      (8.8)


      (19.6)


      (22.1)

      (14.6)


      (15.9)

      Viekira

      —


      36


      36


      (100.0)


      (77.2)


      (79.2)

      (77.6)


      (79.6)
















      Other Key Products

      3,019


      1,770


      4,789


      (3.2)


      (0.3)


      (3.9)

      (2.1)


      (3.4)

      Creon

      1,041


      —


      1,041


      12.2


      n/a


      n/a

      12.2


      12.2

      Lupron

      720


      167


      887


      (0.8)


      6.0


      0.8

      0.5


      (0.5)

      Synthroid

      786


      —


      786


      1.3


      n/a


      n/a

      1.3


      1.3

      Synagis

      —


      718


      718


      n/a


      0.9


      (1.2)

      0.9


      (1.2)

      Duodopa

      97


      364


      461


      20.4


      9.8


      4.2

      11.7


      7.2

      Sevoflurane

      74


      274


      348


      2.0


      (9.5)


      (13.8)

      (7.4)


      (10.9)

      Kaletra

      38


      245


      283


      (31.0)


      (9.5)


      (12.9)

      (12.9)


      (15.8)

      AndroGel

      172


      —


      172


      (63.3)


      n/a


      n/a

      (63.3)


      (63.3)

      Orilissa

      91


      2


      93


      >100.0


      n/m


      n/m

      >100.0


      >100.0


      Note: "Operational" comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates.


      n/a = not applicable

      n/m = not meaningful


      a   Adjusted net revenues exclude specified items. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Percentage change is calculated using adjusted net revenues.


      b  Reflects profit sharing for Imbruvica international revenues.

      AbbVie Inc.

      Consolidated Statements of Earnings

      Quarter and Twelve Months Ended December 31, 2019 and 2018

      (Unaudited) (In millions, except per share data)



      Fourth Quarter

      Ended December 31


      Twelve Months

      Ended December 31


      2019


      2018


      2019


      2018

      Net revenues

      $

      8,704



      $

      8,305



      $

      33,266



      $

      32,753


      Cost of products sold

      2,006



      2,022



      7,439



      7,718


      Selling, general and administrative

      1,951



      1,929



      6,942



      7,399


      Research and development

      1,542



      6,495



      6,407



      10,329


      Acquired in-process research and development

      139



      300



      385



      424


      Other operating expense (income)

      (890)



      —



      (890)



      500


      Total operating costs and expenses

      4,748



      10,746



      20,283



      26,370










      Operating earnings (loss)

      3,956



      (2,441)



      12,983



      6,383










      Interest expense, net

      455



      319



      1,509



      1,144


      Net foreign exchange loss

      11



      6



      42



      24


      Other expense (income), net

      416



      (393)



      3,006



      18


      Earnings (loss) before income taxes

      3,074



      (2,373)



      8,426



      5,197


      Income tax expense (benefit)

      273



      (547)



      544



      (490)


      Net earnings (loss)

      $

      2,801



      $

      (1,826)



      $

      7,882



      $

      5,687










      Diluted earnings (loss) per share

      $

      1.88



      $

      (1.23)



      $

      5.28



      $

      3.66










      Weighted-average diluted shares outstanding

      1,485



      1,496



      1,484



      1,546










      Adjusted diluted earnings per sharea

      $

      2.21



      $

      1.90



      $

      8.94



      $

      7.91










      Adjusted weighted-average diluted shares outstandinga

      1,485



      1,501



      1,484



      1,546




      a

      Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Weighted-average diluted shares outstanding includes the effect of dilutive securities. Due to the GAAP net loss in the fourth quarter ended December 31, 2018, certain shares issuable under stock-based compensation plans that were dilutive on a non-GAAP basis were excluded from the computation of GAAP diluted EPS because the effect would have been antidilutive.

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Quarter Ended December 31, 2019

      (Unaudited) (In millions, except per share data)


      1.     Specified items impacted results as follows:



      4Q19


      Earnings


      Diluted


      Pre-tax


      After-tax


      EPS

      As reported (GAAP)

      $

      3,074



      $

      2,801



      $

      1.88


      Adjusted for specified items:






      Intangible asset amortization

      391



      324



      0.22


      Acquisition related costs

      226



      183



      0.12


      Milestones and other R&D expenses

      217



      193



      0.13


      Acquired IPR&D

      139



      123



      0.08


      Reata divestiture

      (330)



      (297)



      (0.20)


      Litigation matters

      (550)



      (435)



      (0.29)


      Change in fair value of contingent consideration

      438



      438



      0.29


      Restructuring

      19



      15



      0.01


      Tax audit settlement

      —



      (133)



      (0.09)


      Other

      (10)



      82



      0.06


      As adjusted (non-GAAP)

      $

      3,614



      $

      3,294



      $

      2.21



      Acquisition related costs reflect transaction and financing costs related to the proposed Allergan acquisition. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Litigation matters includes the settlement of an intellectual property dispute with a third party. Restructuring is primarily associated with streamlining global operations. Other primarily includes the impacts of tax law changes and U.S. tax reform.

      2.     The impact of the specified items by line item was as follows:



      4Q19


      Cost of

      products
      sold


      SG&A


      R&D


      Acquired

       IPR&D


      Other
      operating
      expense
      (income)


      Interest
      expense,
      net


      Other
      (income)
      expense,
      net

      As reported (GAAP)

      $

      2,006



      $

      1,951



      $

      1,542



      $

      139



      $

      (890)



      $

      455



      $

      416


      Adjusted for specified items:














      Intangible asset amortization

      (391)



      —



      —



      —



      —



      —



      —


      Acquisition related costs

      —



      (53)



      —



      —



      —



      (173)



      —


      Milestones and other R&D expenses

      —



      —



      (217)



      —



      —



      —



      —


      Acquired IPR&D

      —



      —



      —



      (139)



      —



      —



      —


      Reata divestiture

      —



      —



      —



      —



      330



      —



      —


      Litigation matters

      —



      —



      —



      —



      550



      —



      —


      Change in fair value of contingent consideration

      —



      —



      —



      —



      —



      —



      (438)


      Restructuring

      (10)



      (15)



      6



      —



      —



      —



      —


      Other

      —



      —



      —



      —



      10



      —



      —


      As adjusted (non-GAAP)

      $

      1,605



      $

      1,883



      $

      1,331



      $

      —



      $

      —



      $

      282



      $

      (22)


      3.     The adjusted tax rate for the fourth quarter of 2019 was 8.8 percent, as detailed below:



      4Q19


      Pre-tax

      earnings


      Income

      taxes


      Tax rate

      As reported (GAAP)

      $

      3,074



      $

      273



      8.9

      %

      Specified items

      540



      47



      8.6

      %

      As adjusted (non-GAAP)

      $

      3,614



      $

      320



      8.8

      %

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Quarter Ended December 31, 2018

      (Unaudited) (In millions, except per share data)


      1.     Specified items impacted results as follows:



      4Q18


      Earnings (Loss)


      Diluted


      Pre-tax


      After-tax


      EPS

      As reported (GAAP)

      $

      (2,373)



      $

      (1,826)



      $

      (1.23)


      Adjusted for specified items:






      Intangible asset amortization

      320



      262



      0.18


      Milestones and other R&D expenses

      50



      50



      0.03


      Acquired IPR&D

      300



      300



      0.20


      Stemcentrx-related impairment

      4,642



      4,117



      2.75


      Charitable contributions

      115



      89



      0.06


      Change in fair value of contingent consideration

      46



      46



      0.03


      Litigation reserves

      7



      6



      —


      Impacts of U.S. tax reform

      —



      (86)



      (0.05)


      Tax audit settlement

      —



      (131)



      (0.09)


      Other

      44



      35



      0.02


      As adjusted (non-GAAP)

      $

      3,151



      $

      2,862



      $

      1.90



      Milestones and other R&D expenses are associated with milestone payments for previously announced collaborations. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Stemcentrx-related impairment refers to the net impact of the intangible asset impairment and the related fair value adjustment to contingent consideration liabilities. Impacts of U.S. tax reform primarily reflects a net tax benefit related to the timing of the new legislation's phase in on certain subsidiaries. Other primarily includes restructuring charges associated with streamlining global operations.

      2.     The impact of the specified items by line item was as follows:



      4Q18


      Cost of

      products
      sold


      SG&A


      R&D


      Acquired

       IPR&D


      Other
      (income)
      expense, net

      As reported (GAAP)

      $

      2,022



      $

      1,929



      $

      6,495



      $

      300



      $

      (393)


      Adjusted for specified items:










      Intangible asset amortization

      (320)



      —



      —



      —



      —


      Milestones and other R&D expenses

      —



      —



      (50)



      —



      —


      Acquired IPR&D

      —



      —



      —



      (300)



      —


      Stemcentrx-related impairment

      —



      —



      (5,070)



      —



      428


      Charitable contributions

      —



      (115)



      —



      —



      —


      Change in fair value of contingent consideration

      —



      —



      —



      —



      (46)


      Litigation reserves

      —



      (7)



      —



      —



      —


      Other

      (28)



      (10)



      (6)



      —



      —


      As adjusted (non-GAAP)

      $

      1,674



      $

      1,797



      $

      1,369



      $

      —



      $

      (11)


      3.     The adjusted tax rate for the fourth quarter of 2018 was 9.1 percent, as detailed below:



      4Q18


      Pre-tax

      earnings (loss)


      Income

      taxes


      Tax rate

      As reported (GAAP)

      $

      (2,373)



      $

      (547)



      23.1

      %

      Specified items

      5,524



      836



      15.1

      %

      As adjusted (non-GAAP)

      $

      3,151



      $

      289



      9.1

      %

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Twelve Months Ended December 31, 2019

      (Unaudited) (In millions, except per share data)


      1.     Specified items impacted results as follows:



      12M19


      Earnings


      Diluted


      Pre-tax


      After-tax


      EPS

      As reported (GAAP)

      $

      8,426



      $

      7,882



      $

      5.28


      Adjusted for specified items:






      Intangible asset amortization

      1,553



      1,286



      0.86


      Acquisition related costs

      415



      338



      0.23


      Milestones and other R&D expenses

      312



      288



      0.20


      Acquired IPR&D

      385



      364



      0.25


      Reata divestiture

      (330)



      (297)



      (0.20)


      Litigation matters

      (523)



      (414)



      (0.28)


      Change in fair value of contingent consideration

      3,182



      3,184



      2.14


      Restructuring

      207



      168



      0.10


      Stemcentrx-related impairment

      939



      823



      0.56


      Tax audit settlement

      —



      (400)



      (0.27)


      Other

      10



      102



      0.07


      As adjusted (non-GAAP)

      $

      14,576



      $

      13,324



      $

      8.94



      Acquisition related costs reflect transaction and financing costs related to the proposed Allergan acquisition. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Litigation matters includes the settlement of an intellectual property dispute with a third party. Restructuring is primarily associated with streamlining global operations. Stemcentrx-related impairment refers to the net impact of the intangible asset impairment and the related fair value adjustment to contingent consideration liabilities. Other primarily includes the impacts of tax law changes and U.S. tax reform.

      2.     The impact of the specified items by line item was as follows:



      12M19


      Cost of

      products
      sold


      SG&A


      R&D


      Acquired

       IPR&D


      Other
      operating
      expense
      (income)


      Interest
      expense,
      net


      Other
      (income)
      expense,
      net

      As reported (GAAP)

      $

      7,439



      $

      6,942



      $

      6,407



      $

      385



      $

      (890)



      $

      1,509



      $

      3,006


      Adjusted for specified items:














      Intangible asset amortization

      (1,553)



      —



      —



      —



      —



      —



      —


      Acquisition related costs

      —



      (103)



      —



      —



      —



      (312)



      —


      Milestones and other R&D expenses

      —



      —



      (312)



      —



      —



      —



      —


      Acquired IPR&D

      —



      —



      —



      (385)



      —



      —



      —


      Reata divestiture

      —



      —



      —



      —



      330



      —



      —


      Litigation matters

      —



      (27)



      —



      —



      550



      —



      —


      Change in fair value of contingent consideration

      —



      —



      —



      —



      —



      —



      (3,182)


      Restructuring

      (25)



      (125)



      (57)



      —



      —



      —



      —


      Stemcentrx-related impairment

      —



      —



      (1,030)



      —



      —



      —



      91


      Other

      (1)



      —



      (19)



      —



      10



      —



      —


      As adjusted (non-GAAP)

      $

      5,860



      $

      6,687



      $

      4,989



      $

      —



      $

      —



      $

      1,197



      $

      (85)


      3.     The adjusted tax rate for the full-year 2019 was 8.6 percent, as detailed below:



      12M19


      Pre-tax

      earnings


      Income

      taxes


      Tax rate

      As reported (GAAP)

      $

      8,426



      $

      544



      6.5

      %

      Specified items

      6,150



      708



      11.5

      %

      As adjusted (non-GAAP)

      $

      14,576



      $

      1,252



      8.6

      %

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Twelve Months Ended December 31, 2018

      (Unaudited) (In millions, except per share data)


      1.     Specified items impacted results as follows:



      12M18


      Earnings


      Diluted


      Pre-tax


      After-tax


      EPS

      As reported (GAAP)

      $

      5,197



      $

      5,687



      $

      3.66


      Adjusted for specified items:






      Intangible asset amortization

      1,294



      1,063



      0.69


      Milestones and other R&D expenses

      137



      137



      0.09


      Acquired IPR&D

      424



      424



      0.27


      Calico collaboration

      500



      500



      0.32


      Stemcentrx-related impairment

      4,642



      4,117



      2.66


      Charitable contributions

      350



      271



      0.18


      Change in fair value of contingent consideration

      478



      478



      0.31


      Litigation reserves

      353



      282



      0.18


      Impacts of U.S. tax reform

      —



      (620)



      (0.40)


      Tax audit settlement

      —



      (131)



      (0.09)


      Other

      82



      74



      0.04


      As adjusted (non-GAAP)

      $

      13,457



      $

      12,282



      $

      7.91



      Milestones and other R&D expenses are associated with milestone payments for previously announced collaborations. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Stemcentrx-related impairment refers to the net impact of the intangible asset impairment and the related fair value adjustment to contingent consideration liabilities. Impacts of U.S. tax reform primarily reflects a net tax benefit related to the timing of the new legislation's phase in on certain subsidiaries. Other primarily includes restructuring charges associated with streamlining global operations and milestone revenue under a previously announced collaboration.

      2.     The impact of the specified items by line item was as follows:



      12M18


      Net
      revenues


      Cost of

      products
      sold


      SG&A


      R&D


      Acquired

       IPR&D


      Other
      operating
      expense
      (income)


      Other
      (income)
      expense,
      net

      As reported (GAAP)

      $

      32,753



      $

      7,718



      $

      7,399



      $

      10,329



      $

      424



      $

      500



      $

      18


      Adjusted for specified items:














      Intangible asset amortization

      —



      (1,294)



      —



      —



      —



      —



      —


      Milestones and other R&D expenses

      —



      —



      —



      (137)



      —



      —



      —


      Acquired IPR&D

      —



      —



      —



      —



      (424)



      —



      —


      Calico collaboration

      —



      —



      —



      —



      —



      (500)



      —


      Stemcentrx-related impairment

      —



      —



      —



      (5,070)



      —



      —



      428


      Charitable contributions

      —



      —



      (350)



      —



      —



      —



      —


      Change in fair value of contingent consideration

      —



      —



      —



      —



      —



      —



      (478)


      Litigation reserves

      —



      —



      (353)



      —



      —



      —



      —


      Other

      (20)



      (62)



      (11)



      (29)



      —



      —



      —


      As adjusted (non-GAAP)

      $

      32,733



      $

      6,362



      $

      6,685



      $

      5,093



      $

      —



      $

      —



      $

      (32)


      3.     The adjusted tax rate for the full-year 2018 was 8.7 percent, as detailed below:



      12M18


      Pre-tax

      earnings


      Income

      taxes


      Tax rate

      As reported (GAAP)

      $

      5,197



      $

      (490)



      (9.4)

      %

      Specified items

      8,260



      1,665



      20.2

      %

      As adjusted (non-GAAP)

      $

      13,457



      $

      1,175



      8.7

      %

      SOURCE AbbVie

      Modal title

      Also from this source

      Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

      Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from HARMONY IN DIVERSITY and HALO, two Phase 4 studies of aesthetic...

      Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

      Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

      Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.